NEW YORK (GenomeWeb News) – A National Cancer Institute review panel has recommended that the Wistar Institute Cancer Center receive $14.9 million in renewal funding to support resources and infrastructure for a range of molecular cancer research activities.

The five-year renewal will fund Wistar's shared resources, which include molecular screening and imaging tools and genomics research technologies, Philadelphia-based Wistar said last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.